JayAtl
BANNED
- Joined
- Nov 18, 2010
- Messages
- 8,812
- Reaction score
- -14
you can't blame them, they have seen how effective drone technology is on the neighbor and want to copy it
India not willing to play by the rules: US lawmakers
- Thread starter Spring Onion
- Start date
you can't blame them, they have seen how effective drone technology is on the neighbor and want to copy it
ok.. USA now must attack India for this
weapon of mass trade unfairness
shree835
BANNED
- Joined
- Jun 26, 2010
- Messages
- 3,005
- Reaction score
- -19
- Country
- Location
How can you talk like a BURBAK ? Only thing I would like to say that We cannot play by American rule; we have to safe guard Indian People Interest And this is matter of life saving drugs.
Thorough Pro
ELITE MEMBER
- Joined
- Aug 23, 2008
- Messages
- 13,232
- Reaction score
- -21
- Country
- Location
Life saving through counterfeit drugs? indian pharma companies infringe on valid patents and market counterfeit drugs with the same name. India is famous for being the worlds largest counterfeit drug manufacturing country in the world.
Fake & sub-standard drugs: India, China may be worst offenders - Economic Times
Indian drugmaker Ranbaxy to pay record fine in U.S. | CTV News
Why substandard and fake drugs are rampant in India - Rediff.com Business
Fake & sub-standard drugs: India, China may be worst offenders - Economic Times
Indian drugmaker Ranbaxy to pay record fine in U.S. | CTV News
Why substandard and fake drugs are rampant in India - Rediff.com Business
Desertfalcon
PROFESSIONAL
- Joined
- Jun 14, 2009
- Messages
- 2,249
- Reaction score
- 10
- Country
- Location
...and yet, you are in America.
Chinese-Dragon
RETIRED TTA
- Joined
- Jul 9, 2010
- Messages
- 33,932
- Reaction score
- 52
- Country
- Location
...and yet, you are in America.
Doesn't really change his point though, does it?
SpArK
ELITE MEMBER
- Joined
- May 5, 2010
- Messages
- 22,519
- Reaction score
- 18
- Country
- Location
US ups its pressure on India over generics industry
The US is to step up its pressure on the Indian generic drug industry following criticism from Pfizer of the country's intellectual property (IP) standards.
On a recent visit to India, US Secretary of State John Kerry is believed to have discussed the Obama administration's opposition to the country's generic drug policies, which analysts have warned could discourage pharma from investing in the country.
Indian patent laws, which do not consider new forms of a known substance to be innovative unless it improves efficacy, have stirred much controversy in recent years, following a number of high-profile cases of revoked patents. In April this year, Novartis' cancer drug Gilvec was denied patent protection; a case that followed similar defeats for Roche's hepatitis C drug Pegasys, Merck's asthma treatment Singulair, Gilead's HIV drug Viread and Pfizer's cancer drug Sutent.
During a subcommittee of the House Energy and Commerce Committee last week, chair Lee Terry outlined his concerns over India's IP policies, which he described as a “unfair and discriminatory” and a "threat" to the trade relationship between the US and India.
Speaking at the meeting, Pfizer's chief IP officer, Roy Waldron, argued that India's "unfair practices" have undermined Pfizer's "ability to innovate, create jobs and provide faster access to life-saving medicines". He claimed that the patent laws have had negative effect on Pfizer's ability to recoup R&D costs, "often exceeding $1bn".
"Since early 2012, India's policies and actions have undermined patent rights for at least nine innovative medicines. Many of these medicines have received patent protection in most countries across the world, suggesting that India is an outlier in recognising and enforcing patent rights. This is not only creating significant uncertainty in the market but it also undermines our ability to compete fairly in India, and our willingness to invest there."
Public health experts have argued that India's inexpensive generic drugs are vital to providing life-saving treatments around the world. Democrat Henry Waxman said: “Indian policies regarding IP and access to medicines can genuinely advance public health”, adding that the US's AIDS-relief programme PEPFAR relies heavily on Indian generics to supply medicines in the developing world.
In a move to address concerns, Indian ambassador to the US, Nirupama Rao, has offered US lawmakers an opportunity to discuss the issue of pharmaceutical IP.
"My senior colleagues at the embassy stand prepared to come and meet with your key officials or your constituents to engage in a friendly and substantive exchange of views so as to promote deeper understanding, and to seek mutually satisfactory solutions, in a spirit of friendship," said Rao in a letter to the US legislators, according to The Times of India.
"India has […] a well-settled, stable and robust intellectual property regime. The three main pillars of this regime are comprehensive laws, detailed rules to back them up, and strong enforcement mechanisms, including those for dispute resolution. In India, the IP framework is rooted in law.
"The full complement of our laws on patents, designs, trademarks and geographical indications is in place and these are in compliance with the Trade Related Intellectual Property Rights (TRIPs) of WTO,” she said.
US ups its pressure on India over generics industry - PMLiVE
India's generic drug industry safe and strongly regulated: Government
NEW DELHI: Government defended its lucrative generic drug industry as safe and strongly regulated after the nation's biggest drug firm pleaded guilty to US charges of making adulterated medicines.
In a bid to defend its generic export sector, the government also charged that "isolated reports" of spurious drugs found in global markets and alleged to be from India were "desperate attempts" by other countries hurt by "the strength of the Indian pharma industry".
India's "pharmaceutical sector is a highly regulated one and the exports are heavily guided by various regulatory regimes of the importing countries", the government said in a statement.
The statement came after New Delhi-based Ranbaxy Laboratories, India's largest drug company by sales, pleaded guilty in the United States to criminal charges of making adulterated medicines and agreed to a $500 million settlement.
The fraud, investigated over eight years by US authorities, was brought to light by a whistle-blowing ex-employee, who said Ranbaxy created "a complicated trail of falsified records and dangerous manufacturing practices".
India built a reputation as the "pharmacy to the world" for its production of life-saving generic versions of medicines for poor nations that cost a fraction of brand-name versions.
But analysts have warned that Indian drugmakers may find it tough to win new contracts in their main US market, with the case involving New Delhi-based Ranbaxy raising questions about the safety and quality of Indian-made drugs.
Generic drug firms in India have been a major supplier of copycat medicines to treat diseases such as cancer, TB and AIDS for those who cannot afford expensive branded versions.
The country "has proven international quality standard capabilities", the government said.
It said India enjoys "a unique position of low-cost manufacturing and the highest quality medicine, the best of both the worlds".
India's drug exports totalled $14.6 billion in the financial year to March 31, marking growth of nearly 11 percent from the previous year.
Japanese drug company Daiichi Sankyo which bought Ranbaxy in 2008, has since alleged that the Indian firm's former owners hid vital information about US regulatory inquiries at the time of the $4.6-billion purchase.
The charges have been strongly denied by the billionaire Singh family which used to control the company.
India has long alleged that some complaints about the quality of its generic medicines originate with rival brand-name manufacturers unhappy about the growing use of cheaper knock-off drugs as developed nations tackle soaring health care costs.
India's generic drug industry safe and strongly regulated: Government - Economic Times
The US is to step up its pressure on the Indian generic drug industry following criticism from Pfizer of the country's intellectual property (IP) standards.
On a recent visit to India, US Secretary of State John Kerry is believed to have discussed the Obama administration's opposition to the country's generic drug policies, which analysts have warned could discourage pharma from investing in the country.
Indian patent laws, which do not consider new forms of a known substance to be innovative unless it improves efficacy, have stirred much controversy in recent years, following a number of high-profile cases of revoked patents. In April this year, Novartis' cancer drug Gilvec was denied patent protection; a case that followed similar defeats for Roche's hepatitis C drug Pegasys, Merck's asthma treatment Singulair, Gilead's HIV drug Viread and Pfizer's cancer drug Sutent.
During a subcommittee of the House Energy and Commerce Committee last week, chair Lee Terry outlined his concerns over India's IP policies, which he described as a “unfair and discriminatory” and a "threat" to the trade relationship between the US and India.
Speaking at the meeting, Pfizer's chief IP officer, Roy Waldron, argued that India's "unfair practices" have undermined Pfizer's "ability to innovate, create jobs and provide faster access to life-saving medicines". He claimed that the patent laws have had negative effect on Pfizer's ability to recoup R&D costs, "often exceeding $1bn".
"Since early 2012, India's policies and actions have undermined patent rights for at least nine innovative medicines. Many of these medicines have received patent protection in most countries across the world, suggesting that India is an outlier in recognising and enforcing patent rights. This is not only creating significant uncertainty in the market but it also undermines our ability to compete fairly in India, and our willingness to invest there."
Public health experts have argued that India's inexpensive generic drugs are vital to providing life-saving treatments around the world. Democrat Henry Waxman said: “Indian policies regarding IP and access to medicines can genuinely advance public health”, adding that the US's AIDS-relief programme PEPFAR relies heavily on Indian generics to supply medicines in the developing world.
In a move to address concerns, Indian ambassador to the US, Nirupama Rao, has offered US lawmakers an opportunity to discuss the issue of pharmaceutical IP.
"My senior colleagues at the embassy stand prepared to come and meet with your key officials or your constituents to engage in a friendly and substantive exchange of views so as to promote deeper understanding, and to seek mutually satisfactory solutions, in a spirit of friendship," said Rao in a letter to the US legislators, according to The Times of India.
"India has […] a well-settled, stable and robust intellectual property regime. The three main pillars of this regime are comprehensive laws, detailed rules to back them up, and strong enforcement mechanisms, including those for dispute resolution. In India, the IP framework is rooted in law.
"The full complement of our laws on patents, designs, trademarks and geographical indications is in place and these are in compliance with the Trade Related Intellectual Property Rights (TRIPs) of WTO,” she said.
US ups its pressure on India over generics industry - PMLiVE
India's generic drug industry safe and strongly regulated: Government
NEW DELHI: Government defended its lucrative generic drug industry as safe and strongly regulated after the nation's biggest drug firm pleaded guilty to US charges of making adulterated medicines.
In a bid to defend its generic export sector, the government also charged that "isolated reports" of spurious drugs found in global markets and alleged to be from India were "desperate attempts" by other countries hurt by "the strength of the Indian pharma industry".
India's "pharmaceutical sector is a highly regulated one and the exports are heavily guided by various regulatory regimes of the importing countries", the government said in a statement.
The statement came after New Delhi-based Ranbaxy Laboratories, India's largest drug company by sales, pleaded guilty in the United States to criminal charges of making adulterated medicines and agreed to a $500 million settlement.
The fraud, investigated over eight years by US authorities, was brought to light by a whistle-blowing ex-employee, who said Ranbaxy created "a complicated trail of falsified records and dangerous manufacturing practices".
India built a reputation as the "pharmacy to the world" for its production of life-saving generic versions of medicines for poor nations that cost a fraction of brand-name versions.
But analysts have warned that Indian drugmakers may find it tough to win new contracts in their main US market, with the case involving New Delhi-based Ranbaxy raising questions about the safety and quality of Indian-made drugs.
Generic drug firms in India have been a major supplier of copycat medicines to treat diseases such as cancer, TB and AIDS for those who cannot afford expensive branded versions.
The country "has proven international quality standard capabilities", the government said.
It said India enjoys "a unique position of low-cost manufacturing and the highest quality medicine, the best of both the worlds".
India's drug exports totalled $14.6 billion in the financial year to March 31, marking growth of nearly 11 percent from the previous year.
Japanese drug company Daiichi Sankyo which bought Ranbaxy in 2008, has since alleged that the Indian firm's former owners hid vital information about US regulatory inquiries at the time of the $4.6-billion purchase.
The charges have been strongly denied by the billionaire Singh family which used to control the company.
India has long alleged that some complaints about the quality of its generic medicines originate with rival brand-name manufacturers unhappy about the growing use of cheaper knock-off drugs as developed nations tackle soaring health care costs.
India's generic drug industry safe and strongly regulated: Government - Economic Times
Desertfalcon
PROFESSIONAL
- Joined
- Jun 14, 2009
- Messages
- 2,249
- Reaction score
- 10
- Country
- Location
I think it does. It always amuses me to find those who run my country down......and yet, live off it's largess without embarrassment.
rubyjackass
SENIOR MEMBER
- Joined
- Nov 29, 2008
- Messages
- 3,610
- Reaction score
- 0
- Country
- Location
Not until they come of the bad economy. The reason being, to increase employment they want their companies to see growth which can now happen only by expansion overseas in markets like India. The irony is that even though drug companies are now lobbying to make India 'comply' with IPR regime, claiming it saves jobs in America, the job increment will be only in India because most US and EU companies get their actives mades through Indian contractors, because they cannot pollute US' or EU's environment according to rules. Yet they make politicians lobby for them saying BS like American jobs are hurting. Even though India had never been a major market for these pharma giants.
Spring Onion
PDF VETERAN
- Joined
- Feb 1, 2006
- Messages
- 41,403
- Reaction score
- 19
- Country
- Location
Very right.
It means they want to practice enslavement policy and at the same time want to keep all the earning
...and yet, you are in America.
do you want to punish the State/country for its individuals' wish to live in US?why dont you kick them out instead of pressurising their countries for giving you more business/jobs ?
Arya Desa
BANNED
- Joined
- Sep 23, 2012
- Messages
- 3,301
- Reaction score
- -18
- Country
- Location
H1B. He probably makes much more than you therefore adding a greater percentage to the "your" country than you.
satishkumarcsc
SENIOR MEMBER
- Joined
- Nov 26, 2008
- Messages
- 2,630
- Reaction score
- 0
- Country
- Location
Well you cant ask us to play cricket with baseball rules....So nobody cares...if the Americans want to do business in India they may play by our rules and not theirs.
Americans can in no way influence the policies made by India and that seriously gets on their nerves and they also must realize that this is the most pro-American government that they are going to ever get in the history of Indo-US relationship.
And one personal word from me.. America, we are not Pakistan.
Americans can in no way influence the policies made by India and that seriously gets on their nerves and they also must realize that this is the most pro-American government that they are going to ever get in the history of Indo-US relationship.
And one personal word from me.. America, we are not Pakistan.
RPK
SENIOR MEMBER
- Joined
- Jul 6, 2009
- Messages
- 6,862
- Reaction score
- -6
- Country
- Location
Pakistani's also comes to India for treatment, is that ok Pakistani's also suffer?
